A new analysis from Vizient® shows that drug manufacturers are adjusting pricing strategies in markedly different ways ahead of upcoming Medicare Drug Price Negotiation Program (MDPNP) changes under ...

Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...

Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in a legal tussle with Sandoz over the patent covering the blockbuster inflammatory diseases ...

ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...

These five Dogs of the Dow may be the perfect play for 2026 for growth and income investors wary of volatility and a ...

ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...

Whether you're looking to stop video ads, pop-ups, trackers, or malware, the top ad blockers we've tested help create a cleaner, faster, and more secure online environment. I review privacy tools like ...

Through our Associate, Associate Principal, and Principal program, we provide a clear pathway to ownership… Houston, Texas, December 29, 2025 – MRE Consulting, Ltd., a leading technology consulting ...

Scottsdale-based agency recognized for excellence in crisis communications, corporate communications, public affairs and traditional… This year marks a major milestone for The McRae Agency as it ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...